[Pharmacokinetics of a new aminoglycoside: kanendomycin].
The pharmacokinetics of kanendomycin, a new aminoglycoside derived from kanamycin, has been assessed in 15 volunteers after i.m. administration of 100 and 300 mg and i.v. administration of 100 mg. Analysis of the tricompartmental model adopted for the pharmacokinetic study showed that kanendomycin half-life is similar and perhaps superior to that of gentamycin. The antibiotic's bioavailability is of the order of 70-80% of the dose used.
D000617:Aminoglycosides / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D001682:Biological Availability; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008826:Microbial Sensitivity Tests
D000617:Aminoglycosides; D007612:Kanamycin
Farmacocinetica di un nuovo aminoglicoside: kanendomicina.